ABL Inc. Announces Hiring of Diana Elias as HR Director
(Rockville, MD) – ABL, Inc. (ABL), a leading global viral vector contract manufacturing and research testing service provider to the biopharmaceutical industry, announces the hire of Diana Elias as HR Director. As head of HR, Diana will report to the Chief Executive Officer (CEO), Jarlath Keating, and lead the HR strategic and engagement initiatives at the Rockville, MD site.
Prior to joining ABL, Diana served as the Director of HR at the American Association for Laboratory Accreditation (A2LA) and had responsibility for HR, Customer Care, and the Annual A2LA Tech Forum. Before settling into HR, Diana provided hands-on support in both laboratory and QA roles at BioReliance®, Charles Rivers and Associates, and Harlan Sprague Dawley.
Diana graduated from Hood College with her MBA (concentration in Human Resources) and University of Maryland with her Bachelor’s in Human Resource Management. She also holds her SPHR designation.
Despite changing her career from bench work to HR, Diana has a passion for science and has remained loyal to STEM companies. HR has provided her with the opportunity to enjoy her other passion – people. “In HR, I am able to work with everyone across the organization. I use my past work experience to listen and truly understand the pain points and opportunities for employees – this drives our HR strategy to ensure we give people what they truly want and need.” explains Diana.
“It has been fantastic joining the ABL team!” said Diana. “My HR team will be responsible for establishing and communicating the value proposition for ABL as an employer to biotech enthusiasts all over the DMV. Our CEO is committed to investing in our employees and has provided support to our department to lead the charge. ABL is lucky enough to be in an area rich with research and development. ABL utilizes its strong core of product development expertise, GMP manufacturing and immunological testing capabilities toward advancing your candidate vaccines and therapeutics through preclinical and clinical development. ABL’s experts are producing and testing today’s leading oncolytic viruses, gene therapies, immunotherapies, viral vaccines, and recombinant protein vaccines. There are so many talented, passionate candidates all throughout our area and ABL wants to provide a unique experience for those who select us as an employer, to really focus on the employee journey – prior to, during, and after their time with us. Be on the lookout – ABL strives to be an employer of choice!”
Jarlath Keating, President and CEO of ABL stated, “Diana’s experience in leading HR functions, her understanding of the market and her passion for people make her an ideal fit for ABL and the journey our organization has embarked upon to become a destination employer in the life s56cience industry. We are very excited to have Diana join us and contribute to the growth of our employees and company overall.”
About ABL, Inc.
A leading CDMO and CRO harnessing decades of pioneering science and manufacturing expertise to drive the development of innovative therapies and vaccines. ABL has extensive experience working with diverse organizations—including industry, government and academic entities—to support their quest in improving public health. ABL maintains global GMP facilities meeting U.S. and European regulatory standards, providing GMP manufacture of virus-based oncolytic therapies, gene therapies, vaccines and protein-based immunotherapeutic products. ABL’s CDMO services include bulk drug substance, fill/finish of drug product, process and assay development, and bioanalytical testing.
As a CRO, ABL’s immunologists use an integrated array of optimized immunology and molecular assay platforms to extract immunological correlates of activity and response in both preclinical studies and clinical trials. ABL is a part of the Institut Mérieux, a group of companies dedicated to developing translational science for better patient care globally.
Latest posts by Chris Frew (see all)
- Arcellx Appoints Rami Elghandour as Chairman and Chief Executive Officer - January 26, 2021
- Impulse Dynamics Closes $60 Million Financing | Business Wire - January 14, 2021
- Delfi Diagnostics Announces $100 Million Series A Financing to Develop a New Class of Early Detection Liquid Biopsy for Multiple Cancers - January 14, 2021